Farmak JSC

Located in Kyiv, Ukraine, Farmak JSC is a prominent pharmaceutical company engaged in the development and production of prescription and over-the-counter medicines, medical devices, and dietary supplements. Founded in 1991, Farmak JSC operates from its headquarters in Kyiv, Ukraine, focusing on pharmaceutical development and manufacturing. The company has consistently worked to enhance its product offerings without significantly altering its core operational strategy. Farmak is led by a team of executives, including CEO Grzegorz Zoledziewski, Pavlo Savenko, and Volodymyr Kostiuk.

Farmak is a leading Ukrainian pharmaceutical company that specializes in the development and manufacturing of medicines, including both prescription and over-the-counter products, medical devices, and dietary supplements. The company is committed to enhancing healthcare by creating over 20 new drug formulations each year, while also engaging in the discovery of innovative molecules. Farmak serves a diverse clientele across more than 50 countries, providing high-quality pharmaceutical solutions aimed at improving health outcomes for millions of patients globally. The company’s products are designed to address various health conditions and are manufactured according to stringent quality standards that meet international guidelines.

Key geographical markets for Farmak's products include Europe, Asia, and other regions where they maintain a significant export footprint. Farmak generates revenue through a structured model that includes both business-to-business (B2B) and direct-to-consumer sales channels. The company's transactions typically involve partnerships with wholesalers and retailers, who distribute its pharmaceutical products to various healthcare facilities and pharmacies. Additionally, Farmak's flagship products are designed to meet the needs of healthcare providers and patients alike, which creates a steady demand cycle.

The pricing structure for these products is established to ensure accessibility while maintaining premium quality, aligning with the company's commitment to health and safety. This transactional framework allows Farmak to sustain its position as a leader in the pharmaceutical market and supports its ongoing investment in research and development for future product innovations.